Siemens Healthineers AG (SWX:SHL)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 36.53B |
| Revenue (ttm) | 21.69B |
| Net Income (ttm) | 1.97B |
| Shares Out | n/a |
| EPS (ttm) | 1.76 |
| PE Ratio | 18.52 |
| Forward PE | 14.91 |
| Dividend | 0.92 (2.63%) |
| Ex-Dividend Date | Feb 6, 2026 |
| Volume | n/a |
| Average Volume | n/a |
| Open | n/a |
| Previous Close | 33.97 |
| Day's Range | n/a |
| 52-Week Range | 33.70 - 45.95 |
| Beta | n/a |
| RSI | 31.43 |
| Earnings Date | May 7, 2026 |
About Siemens Healthineers AG
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers in Germany, the United States, rest of Europe, CIS, Africa, the Middle East, the Americas, the Asia Pacific, Japan, and China. It operates in four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment offers magnetic resonance imaging, computed tomography, X-ray, molecular imaging, and ultrasound systems; and software solutions to support the readin... [Read more]
Financial Performance
In fiscal year 2025, Siemens Healthineers AG's revenue was 23.38 billion, an increase of 4.53% compared to the previous year's 22.36 billion. Earnings were 2.14 billion, an increase of 10.40%.
Financial numbers in EURNews
Siemens Plans Spin-off of Siemens Healthineers Stock for 2027 Vote
Siemens Plans Spin-off of Siemens Healthineers Stock for 2027 Vote
Siemens plans shareholder vote on Siemens Healthineers spin-off in February 2027
Siemens said on Friday it planned a shareholder vote on a direct spin-off of Siemens Healthineers shares at its next shareholder meeting in February 2027.
Radiopharm Theranostics Signs Supply Deal With Siemens Healthineers For RAD101
(RTTNews) - Radiopharm Theranostics Ltd. (RADX) said Tuesday it has signed a supply agreement with Siemens Healthineers for RAD101, a novel imaging small molecule targeting fatty acid synthase (FASN) ...
Siemens Healthineers AG Transcript: Pre-close call
Q2 revenue growth is expected below the 5%-6% outlook, with significant FX and tariff headwinds impacting margins and EBIT. Diagnostics faces pronounced declines in China, while hedging and pricing strategies aim to offset cost inflation risks.
Imaginostics Receives Siemens Healthineers Letter of Support as Companies Advance Quantitative MRI Dialogue
ORLANDO, Fla.--(BUSINESS WIRE)-- #Alzheimers--Imaginostics, Inc. today announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions r...
Siemens Healthineers Launches Brain Health Research Portfolio with First Biomarker Assays Now Available
Brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays now available for research use Brain-derived, fully automated Atellica IM P...
Ki Reply and Data Reply Lay the Strategic Foundation for AI Innovation at Siemens Healthineers with “Cerebra”
TURIN, Italy--(BUSINESS WIRE)--Ki Reply and Data Reply, the Reply Group companies specialised respectively in AI-powered software development and data-driven solutions, have partnered with the “CRM Ex...
Siemens Healthineers AG Transcript: Status update
Imaging and Precision Therapy delivered strong growth and margins, offsetting Diagnostics' decline due to China market headwinds. H2 is expected to improve with cost reductions, core lab momentum, and new product launches, while spin-off preparations advance.
Siemens Healthineers Core Businesses Offset Currency, Tariff Challenges
Revenue grew on a comparable basis as results in its imaging and precision therapy business units offset currency and tariff headwinds.
Siemens Healthineers AG Earnings Call Transcript: Q1 2026
Imaging and precision therapy delivered strong growth and margin expansion, offsetting diagnostics' revenue decline driven by structural changes in China. Fiscal 2026 outlook is confirmed, with continued tariff and FX headwinds, and diagnostics expected to face further challenges in Q2.
Siemens Healthineers beats Q1 profit estimates on strong imaging unit margins
Siemens Healthineers reported first-quarter operating profit above market expectations on Thursday, as strong margin performance in its core imaging and cancer-care units helped cushion a slump in its...
5 European AI Stocks to Track in Q1 2026
While the artificial intelligence boom has continued to gather momentum in the United States and China, Europe's strengthening role in AI markets may be undervalued by investors, opening the door to f...
Siemens Healthineers AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
Global leadership in imaging and precision therapy is reinforced by strong R&D, AI-driven innovation, and robust recurring revenues. Photon-counting CT and precision therapy advances drive growth, while prudent financial management and productivity programs address market and tariff headwinds.
Siemens Healthineers AG Transcript: CMD 2025
Clear focus on four major disease areas, with Imaging and Precision Therapy driving 6%-9% annual growth and Diagnostics targeting mid-single digit growth and margin expansion. AI and innovation are central, with strong recurring revenues, disciplined capital allocation, and sustainability goals supporting double-digit EPS growth.
Siemens Healthineers AG Transcript: Status update
Q4 and fiscal 2025 saw solid growth, strong cash generation, and robust order intake, with tariffs and FX presenting headwinds for 2026. Imaging and Varian remain growth drivers, while Diagnostics faces China-specific challenges. Tariff impacts will be fully mitigated over three years.
Siemens Healthineers preparing for potential Siemens's share sale -CFO
Siemens Healthineers is preparing for the possibility that its biggest shareholder Siemens AG may reduce its stake in the medical technology company to less than 50%, its CFO said on Wednesday.
Siemens Healthineers AG Earnings Call Transcript: Q4 2025
Fiscal 2025 ended with strong results, achieving guidance and broad-based growth except in China. Fiscal 2026 guidance anticipates 5%-6% revenue growth, with continued headwinds from tariffs and FX, and flat China revenue. Innovation and operational improvements drive segment performance.
Siemens Healthineers Reports Fall in Profits, Citing Tariffs
Higher comparable revenue stemming from the transformation program of its diagnostics business was offset by a hit from U.S. tariffs.
Siemens Healthineers slightly misses sales expectations in fourth quarter
Siemens Healthineers on Wednesday reported fourth-quarter revenue slightly below analysts' consensus as higher U.S. import tariffs weigh.
New Drug Testing Analyzer from Siemens Healthineers Raises the Bar for Court, Military, and Forensics Testing, Offering Clinical-Quality Results
TARRYTOWN, N.Y.--(BUSINESS WIRE)-- #drugtesting--New drug testing analyzer helps identify substance use, monitor therapeutic and immunosuppressant drugs, and perform serum toxicology testing.
Siemens Healthineers AG Transcript: Pre-Close Call
Q4 is set to be the strongest quarter, though less loaded than last year, with full-year growth guided at 5.5%-6% and EPS at EUR 2.30-2.45. Currency volatility and tariffs are key headwinds, with a combined EUR 0.30 EPS impact expected in 2026.
VedaBio Announces Strategic Agreement with Siemens Healthineers and Series A Extension, Totaling Up to $25 Million
SAN DIEGO--(BUSINESS WIRE)--VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a Series A extension alongside a strategic agreement with Siemens Healthineers...
EVIDENT and Siemens Healthineers Join Efforts to Advance Digital Pathology at Klinikum Ludwigshafen
Collaboration combines AI imaging, diagnostics expertise, and clinical leadership to drive digital pathology forward Collaboration combines AI imaging, diagnostics expertise, and clinical leadership t...
Carna Health and Siemens Healthineers join forces to Advance Kidney Care Innovation
BOSTON--(BUSINESS WIRE)--Carna Health, a digital health company revolutionizing kidney care, announced a strategic agreement with Siemens Healthineers to accelerate adoption of Carna's AI-enabled chro...
Siemens Healthineers AG Transcript: Status update
Q3 2025 saw robust revenue and margin growth, prompting a raised outlook. Tariffs and FX headwinds are expected to weigh on 2026, but mitigation plans are in place. Photon-counting CT and innovation continue to drive segment strength.